This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
May 1, 2026
•
4 min read
🧬 Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia, AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones, UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%
Apr 30, 2026
3 min read
🧬 GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts, Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly, Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases
